



Heart Failure Case Study

Intermountain Health system used Story Health by Innovaccer's AI-powered care orchestration engine to address the challenges they faced in heart failure (HF) care and to fill gaps in medication therapy.

Heart failure is a substantial and growing health problem in the U.S. By 2030. HF is projected to [1]:

50%

Increase in prevalence

2X +

Direct medical costs

Clear evidence shows that medical therapy management can [2,3]:



Significantly reduce morbidity



Reduce hospital admissions



Improve quality of life

However, clinics have struggled to implement GDMT* optimization [4]:

<1% of all qualified patients on target doses of GDMT (2018 CHAMP-HF national study)

*GDMT = Guideline Directed Medical Therapy

Intermountain's existing HF program had made tremendous progress, but gaps in GDMT optimization remained. To address these gaps, Intermountain began piloting Story Health by Innovaccer's AI-powered care model in early 2023.

Story Health by Innovaccer's Al-powered care orchestration engine includes:



Health Coach Support

Specialized care team guiding patients between visits to keep them on track

Integrations + Health Data

Patient provided BP/weight/symptom data + info from EHR to inform changes


Medication Optimization

Protocol-based, AI-powered individualized care plans with alerts enabling rapid titrations


Intermountain observed that early results from the Story Health pilot program have been very promising.

Clinical Results

Early data from patients enrolled in the Story Health by Innovaccer's heart failure program [5]:



Successful GDMT Target Dosing (>50%) in 90 Days




Financial Results

Story Health by Innovaccer's program population vs. matched control group at 6, 12, and 18 month follow-up intervals [5]:

Hospitalization Rate





Intermountain Health sees the value of Story Health by Innovaccer's AI-powered care orchestration engine and plans to:



References:

- 1. Burden of hospitalization for heart failure in the United States; a systematic literature review: Journal of Managed Care & Specialty Pharmacy: Vol 28, No 2 (jmcp.org)
- 2. Moysidis, D.V., et al., Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial. J Cardiovasc Pharmacol, 2023. 81 (3): p. 203-211
- $3.\ Coons, J.C., et al., Impact of a Medication Optimization Clinic on Heart Failure Hospitalizations. Am J Cardiol, 2023. 188: p. 102-109. Am J Cardiol, 2023. Am J Cardiol, 2$
- $4.\ Sharma, A., et al., Optimizing Foundational Therapies in Patients with HFrEF: How Do We Translate These Findings Into Clinical Care? JACC Basic Transl Sci, 2022. 7(5): p. 504517.$
- 5. Intermountain Health data. 2023.